FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics and medicine, namely to a pharmaceutical composition for topical administration used to prevent the viral infections caused by DNA-containing viruses. As active ingredients, the pharmaceutical composition contains 0.001-5.0 wt % of deoxyribonuclease (DNA-ase) and 0.000001-5.0 wt % of alpha-fetoprotein and 0.001-5.0 wt % of glycyrrhizinic acid or a salt thereof: ammonium or dipotassium or trisodium glycyrrhizinate; the carriers are as follows: β-cyclodextrins 0.001-5.0 wt %, 0.05-1.0 wt % of a polymer carrier, and pharmaceutically acceptable carriers or excipients. In addition, the composition can contain 0.001-5.0 wt % of dexpanthenol or sangviritrin, 0.001 -5.0 wt % of ascorbyl palmitate or escin.
EFFECT: invention provides improved stability, potentiated complex antiviral effect.
2 cl, 6 ex, 1 tbl
